Financial reports
10-K
2023 FY
Annual report
27 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
ARS
2022 FY
Annual report to shareholders
8 Sep 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
Current reports
8-K
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
27 Mar 24
8-K
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
13 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Mar 24
8-K
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
12 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Unregistered Sales of Equity Securities
9 Feb 24
8-K
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
8 Feb 24
8-K
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
31 Jan 24
8-K
Business Development Update for Shareholders
3 Jan 24
8-K
Other Events
19 Dec 23
Registration and prospectus
S-8
Registration of securities for employees
27 Mar 24
S-3
Shelf registration
14 Feb 24
424B5
Prospectus supplement for primary offering
6 Dec 23
424B5
Prospectus supplement for primary offering
17 Nov 23
S-3
Shelf registration
20 Oct 23
424B5
Prospectus supplement for primary offering
22 Jun 23
S-8
Registration of securities for employees
29 Mar 23
S-3
Shelf registration
16 Dec 22
424B5
Prospectus supplement for primary offering
12 Apr 22
S-8
Registration of securities for employees
30 Mar 22
Proxies
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
4 Apr 24
DEF 14A
Definitive proxy
1 Sep 23
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEF 14A
Definitive proxy
2 Dec 20
PRE 14A
Preliminary proxy
20 Nov 20
DEFA14A
Additional proxy soliciting materials
15 Oct 19
DEF 14A
Definitive proxy
15 Oct 19
Other
EFFECT
Notice of effectiveness
2 Apr 24
EFFECT
Notice of effectiveness
6 Dec 23
CORRESP
Correspondence with SEC
1 Dec 23
CORRESP
Correspondence with SEC
15 Nov 23
CORRESP
Correspondence with SEC
14 Nov 23
UPLOAD
Letter from SEC
24 Oct 23
EFFECT
Notice of effectiveness
23 Dec 22
CORRESP
Correspondence with SEC
20 Dec 22
UPLOAD
Letter from SEC
20 Dec 22
EFFECT
Notice of effectiveness
21 Oct 20
Ownership
4
Peter Altman
19 Apr 24
SC 13D/A
Frost Gamma Investments Trust
5 Apr 24
4
Peter Altman
28 Mar 24
SC 13D/A
Frost Gamma Investments Trust
27 Feb 24
4
Peter Altman
15 Feb 24
SC 13G/A
SATTERFIELD THOMAS A JR
14 Feb 24
SC 13D/A
Frost Gamma Investments Trust
6 Feb 24
SC 13G/A
Francis Capital Management, LLC
2 Feb 24
4
PHILLIP MD ET AL FROST
22 Jan 24
4
Andrew Scott Blank
19 Oct 23